4D Molecular Therapeutics (FDMT) Return on Capital Employed (2021 - 2026)
4D Molecular Therapeutics (FDMT) posted quarterly Return on Capital Employed of 36.17% for Q1 2026, up 361.0% year-over-year from 7.85% in Q1 2025, and down 2.32% quarter-over-quarter from 35.35% in Q4 2025.
4D Molecular Therapeutics (FDMT) Return on Capital Employed (2021 - 2026) Analysis & Trends
4D Molecular Therapeutics (FDMT) has reported Return on Capital Employed for 6 consecutive years, with 36.17% the latest figure, recorded in Q1 2026.
- In Q1 2026, Return on Capital Employed rose 361.0% year-over-year to 36.17%; the TTM figure through Mar 2026 stood at 36.17% (up 361.0% YoY), while the FY2025 annual figure was 30.71%, up 1391.0% from the prior year.
- Return on Capital Employed slipped to 36.17% in Q1 2026 per FDMT's latest filing, from 35.35% in the prior quarter.
- Across five years, Return on Capital Employed topped out at 21.67% in Q2 2024 and bottomed at 55.96% in Q3 2025.
- Historically, Return on Capital Employed has averaged 36.42% across 5 years, with a median of 35.35% in 2025.
- Annual changes were most pronounced in 2024 — Return on Capital Employed surged 2126 bps — and 2025, when it tumbled 2706 bps.
- 4D Molecular Therapeutics' Return on Capital Employed stood at 43.1% in 2022, then advanced by 21 bps to 34.02% in 2023, then rose by 0 bps to 33.96% in 2024, then fell by 4 bps to 35.35% in 2025, then decreased by 2 bps to 36.17% in 2026.
- Business Quant data shows FDMT's Return on Capital Employed at 36.17% in Q1 2026, 35.35% in Q4 2025, and 55.96% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 20.76% |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 10.74% |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -55.45% |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 13.68% |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -0.20% |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 7.88% |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 26.09% |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -50.93% |
| 10 | 4D Molecular Therapeutics | 856.62 Mn | 495.28 Mn | - | -43.31% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -43.31% |
| Mar 31, 2026 | -36.17% |
| Dec 31, 2025 | -35.35% |
| Sep 30, 2025 | -55.96% |
| Jun 30, 2025 | -47.90% |
| Mar 31, 2025 | -39.78% |
| Dec 31, 2024 | -33.96% |
| Sep 30, 2024 | -28.90% |
| Jun 30, 2024 | -21.67% |
| Mar 31, 2024 | -25.81% |
| Dec 31, 2023 | -34.02% |
| Sep 30, 2023 | -30.96% |
| Jun 30, 2023 | -41.28% |
| Mar 31, 2023 | -47.07% |
| Dec 31, 2022 | -43.10% |
| Sep 30, 2022 | -38.16% |
| Jun 30, 2022 | -34.13% |
| Mar 31, 2022 | -24.89% |
| Dec 31, 2021 | -25.41% |
| Sep 30, 2021 | -28.34% |